arrow
V

Valentina Di Iorio

IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori
H指数:15
被引数:703

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Post-VABB Cavity-Targeted Avidin-Pretargeted [90Y]Y-DOTA-Biotin in Nonpalpable Breast Cancer: A Phase I Activity-Escalation Study (ARTHE)

术后VABB腔内靶向亲和素预靶向[90Y]Y-DOTA-生物素在非可触及乳腺癌中的应用:一项I期剂量递增研究(ARTHE)

Cancers
IF4.4
2026-08-280
OA
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study

177Lu-PSMA-617放射性配体疗法的疗效、毒性和临床结局:一项前瞻性、单臂、II期研究,研究对象为每周期接受5.5 GBq剂量的晚期去势抵抗性前列腺癌患者

2025-11-270
OAAI
Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project

关于α-粒子疗法临床应用及未来潜力的建议:SECURE项目结果的全面综述

2025-10-180
OAAI
ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES Study
2022-01-132
OAAI
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial
2021-07-3117
OAAI
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors
2021-02-1844
OAAI
Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)

mCRPC (转移性去势抵抗性前列腺癌) 患者的靶向 α 治疗: 225Ac-PSMA (前列腺特异性膜抗原) 的预测剂量学和毒性模型

2020-11-0523
OAAI
Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients
2020-05-2047
PREAI